Biopharmaceutical Contract Manufacturing Market Size, Share and Growth Outlook, 2026

Biopharmaceutical Contract Manufacturing Market Snapshot: Market Size, CAGR, and Growth Outlook (2021 to 2034)

The global Biopharmaceutical Contract Manufacturing Market size is forecast to increase from $45.46 Billion in 2026 to $101.05 Billion in 2034 at a CAGR of 10.5% between 2026 and 2034.

The Biopharmaceutical Contract Manufacturing market report provides detailed analysis and outlook of Biopharmaceutical Contract Manufacturing segments including By Service Type (Process Development Services, cGMP Drug Substance, Drug Product, Fill-Finish & Lyophilization Services, Analytical & Quality Control, Packaging & Logistics), By Product (Monoclonal Antibodies, Vaccines, Recombinant Proteins and Peptides, Cell and Gene Therapies, Biosimilars), By Expression System (Mammalian Expression Systems, Microbial Expression Systems, Insect and Plant Expression Systems), By Scale of Operation (Commercial Scale Production, Clinical ), By Development Phase (Pre-clinical Phase, Phase I-II Trials, Phase III Trials & Commercialization) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

Biopharmaceutical Contract Manufacturing Industry Overview

Strategic Expansion Strengthening Biopharmaceutical Manufacturing Capabilities

The biopharmaceutical contract manufacturing industry is experiencing significant transformation as pharmaceutical and biotechnology companies increasingly rely on contract development and manufacturing organizations (CDMOs) to support complex biologic drug production. Growing demand for monoclonal antibodies, recombinant proteins, cell therapies, gene therapies, and sterile injectable products is driving investment in advanced manufacturing infrastructure and specialized production capabilities. Contract manufacturers are expanding service offerings to provide integrated development, scale-up, fill-finish, and commercial manufacturing solutions that help drug developers accelerate product commercialization while reducing capital investment requirements.

Acquisitions Enhancing Specialized Manufacturing Services

Industry consolidation continues to play an important role in expanding technical expertise and production capabilities. In May 2026, PCI Pharma Services completed the acquisition of Ajinomoto Althea, a United States-based sterile fill-finish CDMO. The transaction significantly strengthens PCI Pharma Services’ capabilities in handling complex biopharmaceutical formulations and expands its service portfolio within sterile manufacturing operations. As biologic therapies become increasingly sophisticated, demand for advanced fill-finish capabilities continues to rise. Strategic acquisitions such as this enable contract manufacturers to broaden their technical competencies and provide end-to-end support for biopharmaceutical development and commercialization programs.

Portfolio Realignment Driving Focus on Core CDMO Operations

A major industry development has been Lonza’s strategic transformation into a pure-play contract development and manufacturing organization. As part of this initiative, Lonza entered into an agreement to divest its Capsules & Health Ingredients business to Lone Star Funds for approximately USD 3 billion. This portfolio realignment allows the company to focus resources on its core biopharmaceutical CDMO operations. The proceeds from the transaction are being redirected toward organic growth initiatives and manufacturing capacity expansion, reflecting the increasing importance of specialized biologics manufacturing services within the global pharmaceutical supply chain. Such strategic restructuring highlights the industry's emphasis on operational specialization and long-term manufacturing scalability.

Capacity Expansion Supporting Future Biopharmaceutical Demand

Manufacturing infrastructure expansion remains a key priority across the biopharmaceutical contract manufacturing sector. Lonza confirmed that its large-scale mammalian cell culture facility in Visp, Switzerland, has entered the final stages of ramp-up, with full commercial operations scheduled to commence during 2026. The facility is designed to support large-scale biologics production and address growing demand for mammalian cell culture manufacturing capacity. Investments in advanced production infrastructure are critical for meeting the increasing requirements of pharmaceutical and biotechnology companies developing complex biologic therapies. As demand for outsourced biologics manufacturing continues to grow, capacity expansion projects are playing a central role in strengthening global supply capabilities and supporting future therapeutic innovation.

Biopharmaceutical Contract Manufacturing Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global Biopharmaceutical Contract Manufacturing market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Lonza Group AG, Boehringer Ingelheim International GmbH, Samsung Biologics Co., Ltd., WuXi Biologics (Cayman) Inc., Catalent, Inc., Fujifilm Diosynth Biotechnologies, AbbVie Inc. , Thermo Fisher Scientific Inc. , AGC Biologics, Rentschler Biopharma SE. The Biopharmaceutical Contract Manufacturing market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Biopharmaceutical Contract Manufacturing industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-

• Growth Biopharmaceutical Contract Manufacturing Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

• Market Trends, Drivers, Potential Opportunities, and Challenges faced by Biopharmaceutical Contract Manufacturing companies

• Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

• Detailed SWOT Analysis of global and regional Biopharmaceutical Contract Manufacturing markets

• Competitive analysis including business description, product analysis, and financial profiles

• Key country specific analysis detailing key factors shaping the short-term and long-term outlook

• Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

Biopharmaceutical Contract Manufacturing Market Competitive Benchmarking and Company Analysis

Leading companies in Biopharmaceutical Contract Manufacturing industry include- Lonza Group AG, Boehringer Ingelheim International GmbH, Samsung Biologics Co., Ltd., WuXi Biologics (Cayman) Inc., Catalent, Inc., Fujifilm Diosynth Biotechnologies, AbbVie Inc. , Thermo Fisher Scientific Inc. , AGC Biologics, Rentschler Biopharma SE. The Biopharmaceutical Contract Manufacturing market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US Biopharmaceutical Contract Manufacturing Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Biopharmaceutical Contract Manufacturing market remains one of the strongest-performing segments in the country.
The US Biopharmaceutical Contract Manufacturing Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Biopharmaceutical Contract Manufacturing market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Biopharmaceutical Contract Manufacturing industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Biopharmaceutical Contract Manufacturing markets

Canada's strong Biopharmaceutical Contract Manufacturing sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Biopharmaceutical Contract Manufacturing market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany Biopharmaceutical Contract Manufacturing Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest Biopharmaceutical Contract Manufacturing market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Biopharmaceutical Contract Manufacturing population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Biopharmaceutical Contract Manufacturing industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Biopharmaceutical Contract Manufacturing market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Biopharmaceutical Contract Manufacturing sales through 2034

France Biopharmaceutical Contract Manufacturing companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK Biopharmaceutical Contract Manufacturing Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of Biopharmaceutical Contract Manufacturing distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or £280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was £49 billion (14.1%) and voluntary health insurance was £9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.

China Biopharmaceutical Contract Manufacturing Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China Biopharmaceutical Contract Manufacturing market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Biopharmaceutical Contract Manufacturing industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Biopharmaceutical Contract Manufacturing industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India Biopharmaceutical Contract Manufacturing Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian Biopharmaceutical Contract Manufacturing market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil Biopharmaceutical Contract Manufacturing market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa Biopharmaceutical Contract Manufacturing Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

Biopharmaceutical Contract Manufacturing Market Segmentation

By Service Type
Process Development Services
cGMP Drug Substance
Drug Product
Fill-Finish & Lyophilization Services
Analytical & Quality Control
Packaging & Logistics
By Product
Monoclonal Antibodies
Vaccines
Recombinant Proteins and Peptides
Cell and Gene Therapies
Biosimilars
By Expression System
Mammalian Expression Systems
Microbial Expression Systems
Insect and Plant Expression Systems
By Scale of Operation
Commercial Scale Production
Clinical
By Development Phase
Pre-clinical Phase
Phase I-II Trials
Phase III Trials & Commercialization

Top Companies in Biopharmaceutical Contract Manufacturing Industry

Lonza Group AG
Boehringer Ingelheim International GmbH
Samsung Biologics Co., Ltd.
WuXi Biologics (Cayman) Inc.
Catalent, Inc.
Fujifilm Diosynth Biotechnologies
AbbVie Inc.
Thermo Fisher Scientific Inc.
AGC Biologics
Rentschler Biopharma SE

Countries Included

• North America- US, Canada, Mexico

• Europe- Germany, France, UK, Spain, Italy, Nordics, Others

• Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others

• Latin America- Brazil, Argentina, Others

• Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa

Latest Market Updates In Healthcare

Support this report with fresh, same-industry updates that strengthen topical depth and internal linking.

Market Update

Low MOQ, High-Mix Production Models for Indie & DTC Brands

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025

Market Update

Rise of Functional and Clinical-Grade Skincare

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025